Results 211 to 220 of about 116,563 (269)
Bioinformatics and computational exploration of novel inhibitors targeting KRAS G12C mutant protein in lung adenocarcinoma. [PDF]
Discov OncolTang G, Ding H, Gong Y.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Chemical Biology, 2021
The protein KRAS has for decades been considered a holy grail of cancer drug discovery. For most of that time, it has also been considered undruggable. Since 2018, five compounds have entered the clinic targeting a single mutant form of KRAS, G12C. Here, we review each of these compounds along with additional approaches to targeting this and other ...
Daniel A, Erlanson, Kevin R, Webster
openaire +2 more sources
The protein KRAS has for decades been considered a holy grail of cancer drug discovery. For most of that time, it has also been considered undruggable. Since 2018, five compounds have entered the clinic targeting a single mutant form of KRAS, G12C. Here, we review each of these compounds along with additional approaches to targeting this and other ...
Daniel A, Erlanson, Kevin R, Webster
openaire +2 more sources
European Journal of Cancer, 2009
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab have been demonstrated to be efficient in the treatment of irinotecan-resistant and chemorefractory metastatic colorectal cancer (mCRC) respectively. However, these costly and potentially toxic treatments are only efficient in a small proportion of patients.
Pierre, Laurent-Puig +2 more
openaire +2 more sources
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab have been demonstrated to be efficient in the treatment of irinotecan-resistant and chemorefractory metastatic colorectal cancer (mCRC) respectively. However, these costly and potentially toxic treatments are only efficient in a small proportion of patients.
Pierre, Laurent-Puig +2 more
openaire +2 more sources
The Journal of Pathology, 2009
Abstract Somatic KRAS mutation is an early well‐known event in colorectal carcinogenesis but a complete understanding of RAS function and dysfunction in colorectal cancer is still to come.
Jehad, Abubaker +11 more
openaire +2 more sources
Abstract Somatic KRAS mutation is an early well‐known event in colorectal carcinogenesis but a complete understanding of RAS function and dysfunction in colorectal cancer is still to come.
Jehad, Abubaker +11 more
openaire +2 more sources